Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

by Herrmann, Ken , Gericke, Germo , Morris, Michael J , Krause, Bernd J , Chi, Kim N , Nordquist, Luke T , DeSilvio, Michelle , Kpamegan, Euloge , Fizazi, Karim , El-Haddad, Ghassan , Park, Chandler H , Vaishampayan, Nitin , de Bono, Johann , Tagawa, Scott T , Armour, Alison , Messmann, Richard A , Pérez-Contreras, Wendy J , Sartor, Oliver , Beer, Tomasz M , Rahbar, Kambiz

in Adverse events / Aged / Aged, 80 and over / Androgen receptors / Androgens / Antigens / Biomarkers / Cancer therapies / Castration / Chemotherapy / Combined Modality Therapy / Computed tomography / Dipeptides - therapeutic use / Disease control / Drug dosages / Drug withdrawal / FDA approval / Gallium / Hematology / Heterocyclic Compounds, 1-Ring - therapeutic use / Humans / Immunotherapy / Kallikreins - antagonists & inhibitors / Lutetium - adverse effects / Lutetium - therapeutic use / Magnetic resonance imaging / Male / Medical prognosis / Metastases / Metastasis / Microenvironments / Middle Aged / Oncology / Pain / Patients / Positron-Emission Tomography / Prostate - diagnostic imaging / Prostate cancer / Prostate Disease / Prostate Disease General / Prostate-Specific Antigen - antagonists & inhibitors / Prostate-Specific Antigen - therapeutic use / Prostatic Neoplasms, Castration-Resistant - diagnostic imaging / Prostatic Neoplasms, Castration-Resistant - drug therapy / Prostatic Neoplasms, Castration-Resistant - mortality / Prostatic Neoplasms, Castration-Resistant - radiotherapy / Quality of life / Radiation / Radioisotopes - adverse effects / Radioisotopes - therapeutic use / Radium / Survival Analysis / Treatments in Oncology / Urology

2021

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

2021

Confirm

Do you wish to request the book?

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

2021

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Herrmann, Ken,

Gericke, Germo,

Morris, Michael J,

Krause, Bernd J,

Chi, Kim N,

Nordquist, Luke T,

DeSilvio, Michelle,

Kpamegan, Euloge,

Fizazi, Karim,

El-Haddad, Ghassan,

Park, Chandler H,

Vaishampayan, Nitin,

de Bono, Johann,

Tagawa, Scott T,

Armour, Alison,

Messmann, Richard A,

Pérez-Contreras, Wendy J,

Sartor, Oliver,

Beer, Tomasz M,

Rahbar, Kambiz

2021

Overview

Guiding the beta-emitting isotope lutetium-177 to prostate cancer lesions with the prostate-specific membrane antigen–targeted radioligand 177 Lu-PSMA-617 plus using standard care was compared with standard care in patients with metastatic castration-resistant prostate cancer. The radioligand therapy prolonged progression-free and overall survival. Adverse effects were more common, but quality of life was maintained.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

/ Aged